INSMNasdaqPharmaceutical PreparationsFiscal year ends December 31

INSMED Inc

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$95.29−0.98 (-1.02%)

Close on Oct 19, 2026

Market cap: $20.71B
P/E (TTM): –
Dividend yield: –

INSMED Inc income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	606	364	305	245	188	164	136	9.84	0	0	0	–	12	0	4.42	6.92	10
Cost of Revenue	123	86	66	55	44	40	24	2.42	0	0	–	–	–	–	–	–	–
Gross Profit	483	278	240	190	144	125	112	7.41	0	0	–	–	–	–	–	–	–
Research & Development	771	598	571	398	273	181	132	145	110	123	74	56	44	30	29	4.70	9.21
Selling, General & Admin	701	461	345	266	–	–	–	–	–	–	–	–	–	–	–	–	–
General & Administrative	–	–	345	266	234	204	211	168	79	51	43	31	22	13	12	10	9.84
Operating Expenses	–	–	–	–	–	–	–	–	189	173	117	87	67	42	66	15	19
Total Costs & Expenses	1,853	1,242	1,015	703	564	430	372	317	189	173	–	–	–	–	–	–	–
Operating Income	-1,247	-878	-710	-457	-375	-265	-235	-307	-189	-173	-117	-87	-55	-42	-62	-8.09	-8.67
Interest Expense	84	85	82	26	40	30	28	25	5.93	3.50	2.89	2.42	2.41	0.76	0.01	0.11	0.78
Other Non-Operating Income	-1.84	0.03	1.86	-5.94	-3.33	0.41	-0.53	0.60	0.30	0.12	-0.03	0.14	-0.03	0.01	0.00	–	–
Asset Impairment Charges	–	–	–	–	–	–	–	–	–	–	–	–	–	0	26	0	0
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	–	–	–	–	-0.01	0.00	0.01	0.00	0	127
Pretax Income	-1,272	-910	-747	-480	-436	-293	-254	-324	-193	-176	-120	-90	-57	-41	-60	-6.36	119
Income Tax Expense	5.03	3.71	2.56	1.38	-1.76	1.40	0.78	0.20	-0.27	0.10	-1.97	-10	-1.22	0	0	0.08	0.48
Net Income	-1,277	-914	-750	-482	-435	-294	-254	-324	-193	-176	-118	-79	-56	-41	-60	-6.43	118
Net Income to Common	-1,277	-914	-750	-482	-435	-294	-254	-324	-193	-176	-118	-79	-56	-41	-69	-6.43	118
EPS (Basic)(per share)	-6.42	-5.57	-5.34	-3.91	-3.88	-3.01	-3.01	-4.22	-2.89	-2.85	-2.02	-1.84	-1.60	-1.56	-2.95	-0.49	9.31
EPS (Diluted)(per share)	-6.42	-5.57	-5.34	-3.91	-3.88	-3.01	-3.01	-4.22	-2.89	-2.85	-2.02	-1.84	-1.60	-1.56	-2.95	-0.49	9.30
Shares Outstanding (Basic, Weighted)(shares)	199	164	140	123	112	98	85	77	67	62	59	43	35	27	23	13	0.01
Shares Outstanding (Diluted, Weighted)(shares)	199	164	140	123	112	98	85	77	67	62	59	43	35	27	23	13	0.01
EBITDA	–	–	-704	-452	-366	-256	-230	-304	-186	-171	-116	-86	-54	-42	-61	-8.04	-7.97

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 83.5%
Operating margin: -73.9%
Net margin: -76.9%
Return on equity, FY2025: -249.3%

Financial strength

Current ratio: 3.72
Debt to equity: 0.72
Debt to assets: 25.8%
Cash to current liabilities: 124.2%

Valuation

P/E ratio: –
Price to sales: 18.21
Price to book: 27.34
Dividend yield: –